


The NCI's Human Tumor Atlas Network

NCI Team in Alphabetical Order: Chamelli Jhappan, *Erika Kim**, Erin Beck, Indu Kohaar, *Jacob Kagan**, Jerry Li, Justin Benavidez, Miguel Ossandon, Nick Hodges, *Richard Mazurchuk**, Sean Hanlon, *Shannon Hughes**, Sharmistha Ghosh-Janjigian, Sidney Fu, Sudhir Srivastava, *Tracy Lively** (**Former Members*)


The NCI Human Tumor Atlas Network (HTAN)

Overarching program goal: Construct dynamic 3D atlases of human cancers

- **Integrate** molecular, cellular, and tumor tissue composition and architecture, including the microenvironment and immune milieu
- Describe **transitions during cancer:** pre-malignant lesions to malignancy, locally invasive to metastatic cancer
- Represent a **diverse patient population**
- Enable **predictive modeling** to refine detection and therapeutic choices for patients.



Tumor Atlases Facilitating an Era of Precision Medicine






HTAN Marker Paper, Cell 2020:
<https://doi.org/10.1016/j.cell.2020.03.053>

HTAN Principles

- **Community Resource** – create a community resource that catalyzes cancer research across disciplines
- **Complementary Approaches** – strengths and weaknesses will be discovered as a Network; expect to work together
- **Open Communication** – accelerate science by breaking down walls; strive towards interoperability
- **Data and Resource Sharing** – requirement for success; expect aggressive public data/resource release timelines

Building Multimodal and Spatial Atlases



HTAN Structure


Normal → Pre-malignant → Malignant → Metastatic → Responsive → Resistant

5 Pre-Cancer Atlas Centers

5 Tumor Atlas Centers

HTAN-Data Coordinating Center

HTAN Steering Committee



Precancer Atlas Subcommittee



Advisory Committee for Data Coordination (ACDC)



Computational Alignment WG



Methods WG



Visualization WG



Translational WG



Outreach WG

Visit the HTAN Data Portal:

<https://data.humantumoratlas.org/>

HTAN Data Coordinating Center (DCC)



Alex



Dar'ya



Adam



Ethan



Milen



Rochelle



Ashley



Niki



Vésteinn



Bill



Dave



Ino

Four partner institutions

- Dana-Farber Cancer Institute
- Sage Bionetworks
- Institute for Systems Biology
- Memorial Sloan-Kettering Cancer Center

Aaron Lisman

Lisa Pasquale

Onur Sumer

Bill Clifford

Xiang Li

Subhi Nandakumar

Tiarah Thomas

HTAN Tumor Types: Phase 1 (2018–2024)

LUNG

Avrum Spira and Steven Dubinett
Boston University and University of California Los Angeles

Dana Pe'er and Christine Icabuzio-Donahue
Memorial Sloan Kettering Cancer Center

Molecular and Cellular Characterization

PANCREAS

Dana Pe'er and Christine Icabuzio-Donahue
Memorial Sloan Kettering Cancer Center

MCL Consortium Pre-Cancr Atlas Pilot

and Samuel Achilefu
Washington University in St. Louis


COLON

Michael Snyder and James Ford
Stanford University

Robert Coffey, Ken Lau and Martha Shrubsole
Vanderbilt University

Bruce Johnson and Aviv Regev
Dana-Farber Cancer Institute

FNLCR and Broad Institute
Tumor Atlas Pilot



BREAST

Shelley Hwang, Carlo Maley and Robert West
Duke University, Arizona State University and Stanford University

Joe Gray, Gordon Mills, Jeremy Goecks and George Thomas
Oregon Health and Science University

Bruce Johnson and Aviv Regev
Dana-Farber Cancer Institute

Li Ding, Ryan Fields, William Gillanders and Samuel Achilefu
Washington University in St. Louis

Frederick National Laboratory for Cancer Research (FNLCR)
and Broad Institute Tumor Atlas Pilot

MCL Consortium Pre-Cancr Atlas Pilot

SKIN


Peter Sorger, Sandro Santagata and Jon Aster
Harvard University and Brigham and Women's Hospital

Bruce Johnson and Aviv Regev
Dana-Farber Cancer Institute and Broad Institute

PEDIATRIC

FNLCR and Broad Institute
Tumor Atlas Pilot
glioma / neuroblastoma / sarcoma

Kai Tan and Stephen Hunger
Children's Hospital of Philadelphia
glioma / neuroblastoma /
very high risk acute lymphoblastic leukemia




Collaborative Efforts to Achieve Goals Collectively

Phase 1 Trans-Network Projects

Build an interactive consortium through collaborations

Address common technical & biological opportunities



Common Themes Across Tumor Types and Analyses

- Recurring cellular spatial patterns that typify **co-evolution of tumor and stroma** emerging as drivers for progression and resistance
- **Discovery of rare, transitional, dedifferentiated and/or plastic tumor cell types** - often conserved across tumor subtypes and correlated with poor outcome
- Deep **exploration of stroma, immune and tumor cell interactions**
 - Regulation of tumor growth via **immune-suppressive signaling circuits** and cancer subtype-specific **spatially organized immune-malignant cell networks**
 - Cancer-associated fibroblasts (CAFs) act as **CAF-subtype-specific TME remodelers** that impact immune responses

~200

Total HTAN publications
and preprints

20+

Primary Atlases
Publications

50+


New analytical or
experimental tools

HTAN Impact

Primary research papers citing HTAN support – 235

50% of all NIH-funded papers have a RCR < 1

Median 16 Atlas Papers RCR = 8.08
> 98.8% of all NIH-funded papers



This is the distribution of RCR values for approximately 31M papers indexed on PubMed.

HTAN Tumor Types: Phase 2 (Launched in Fall 2024)

SKIN

Melanoma and Cutaneous Squamous Cell Carcinoma

Alan Shain, Boris Bastian and Iwei Yeh
University of California, San Francisco

PANCREAS

Rosalie Sears, Elana Fertig, Jonathan Brody and Laura Wood
Oregon Health & Science University

BRAIN


Long Cai, Richard Everson, Matthew Thomson and Barbara Wold
California Institute of Technology

GASTRIC

Linghua Wang, Tae Hyun Hwang, Mingyao Li and Paul Mansfield
MD Anderson

MULTIPLE MYELOMA

Irene Ghobrial
Dana Farber Cancer Institute



PROSTATE

Li Ding, Feng Chen, Eric Kim and Russell Pachynski
Washington University in St. Louis

COLON

Ken Lau and Jeffery Spraggins
Vanderbilt University

OVARY

Samuel Mok, Michael Birrer and Sammy Ferri-Borgogno
MD Anderson


LYMPHOMA

Rong Fan, Stephanie Halene, Zongming Ma and Mina Xu
Yale University

PEDIATRIC SOLID TUMORS

Rhabdomyosarcoma, Neuroblastoma and Wilms Tumor

Shahab Asgharzadeh, James Amatruda and Long Cai
University of California, Los Angeles



HTAN Phase 2: building on the goals of HTAN Phase 1

A publicly available set of spatially-resolved tumor maps describing transitions in cancer for use by the cancer research community




Collaborative Efforts to Achieve Goals Collectively

Phase 2 Trans-Network Projects

Build an interactive consortium through collaborations

Address common technical & biological opportunities




HTAN Data and Resources

[EXPLORE](#)[ANALYSIS TOOLS](#)[MANUAL](#) [ABOUT THE DATA](#) ▾[ABOUT HTAN](#) ▾[SUBMIT DATA](#) ▾[SUPPORT](#) ▾[NEWS](#) ▾[Please cite HTAN](#)

Human Tumor Atlas Network

HTAN is a National Cancer Institute (NCI)-funded Cancer MoonshotSM initiative to construct 3-dimensional atlases of the dynamic cellular, morphological, and molecular features of human cancers as they evolve from precancerous lesions to advanced disease.

[Explore Data](#)[Learn more](#)[Citing HTAN](#)

Data Release V7.0 (Last updated 2025-11-26)

14

Atlases

20

Organs

2372


Cases

10585


Biospecimen

HTAN Generates Data From a Large Number of Assays and Across Many Tumor Types


Data Available from 20 Primary Tumor Sites



Data Available from 30 Different Assays



Making HTAN Data Available and Accessible



Finding HTAN Data

[EXPLORE](#)[ANALYSIS TOOLS](#)[MANUAL](#) [ABOUT THE DATA ▾](#)[ABOUT HTAN ▾](#)[SUBMIT DATA ▾](#)[SUPPORT ▾](#)[NEWS ▾](#)

Publication

Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer



Authors: Chan JM, Quintanal-Villalonga Á, Gao VR, Xie Y, Allaj V, Chaudhary O, Masilionis I, Egger J, Chow A, Walle T, Mattar M, Yarlagadda DVK, Wang JL, Uddin F, Offin M, Ci de Stanchina E, Bhanot UK, Lai WV, Bott MJ, Jones DR, Ruiz A, Baine MK, Li Y, Rekhtman N, Poirier JT, Nawy T, Sen T, Mazutis L, Hollmann TJ, Pe'er D, Rudin CM

Journal: Cancer Cell Pubmed: 34653364 DOI: 10.1016/j.ccell.2021.09.008

Atlas: [Memorial Sloan Kettering Cancer Center](#)

[Overview](#)[Participants 50](#)[Biospecimens 57](#)[scRNA-seq 886](#)[Tools 1](#)[Supporting links](#)

Abstract


Small cell lung cancer (SCLC) is an aggressive malignancy that includes subtypes defined by differential expression of ASCL1, NEUROD1, and POU2F3 (SCLC-A, -N, and -P, respectively). To define and their associated microenvironments across subtypes, we sequenced 155,098 transcriptomes from 21 human biospecimens, including SCLC transcriptomes. We observe greater tumor diversity in SCLC compared to lung adenocarcinoma, driven by canonical, intermediate, and admixed subtypes. We discover a PLCG2-high SCLC phenotype with stem-like features that distinguishes subtypes and predicts clinical outcomes. SCLC exhibits greater immune sequestration and less immune infiltration than lung adenocarcinoma, and SCLC-N shows less immune infiltration than SCLC-A. We identify an immunosuppressive monocyte/macrophage population in SCLC tumors that is particularly associated with the recurrent, PLCG2-high subtype.

Data Availability

Files	CDS/SB-CGC (dbGaP)	Synapse (Open Access)
scRNA-seq Level 1	356	0
scRNA-seq Level 2	52	0
scRNA-seq Level 3	0	208
scRNA-seq Level 4	0	270

Find all data associated with a publication


NCI Cancer Research Data Commons (CRDC)



HTAN Data Jamborees

- Virtual HTAN Jamboree, Dec 2023 & In-Person HTAN Jamboree, Nov 2024
 - ~200 total participant applications
 - ~30 total project pitch submissions
- ~90 participants selected to work on **12 projects**, each addressing a specific scientific question or technical challenge using available HTAN data
 - ✓ Promote the **access and reuse** of HTAN data
 - ✓ Promote **collaborations** to expand the HTAN community
 - ✓ Promote development of **new methods and tools** for HTAN data analysis
 - ✓ Identify **gaps and limitations** of existing HTAN data and resources

HTAN Jamboree Participants





Overview

The National Cancer Institute (NCI) invites you to participate in a data event, titled "NCI Data Jamboree: Enhancing Data Sharing and Utility to Advance Cancer Research," to collaborate in a small collaborative group setting and solve specific problems using a variety of cancer research datasets. The goals include:

- Overcoming barriers to finding, accessing, and using cancer data resources to improve diagnosis and treatment options.
- Promoting interdisciplinary collaborations to expand the size, technical, and scientific diversity of the cancer research community.
- Promoting the development and application of tools, methods, and pipelines for data harmonization, visualization, integration, and analysis.
- Evaluating data quality for replication and reproducibility, or AI-readiness of the data.
- Identifying gaps and limitations of existing data and computing resources.



Dates: November 16 - 18, 2026

Venue: NIH Neuroscience Center Building, 6001 Executive Blvd., Rockville, Maryland 20852.

Format: In-person teams preferred; virtual and hybrid teams allowed.

HTAN is Part of a Larger Atlasing Community

- Annual HTAN Junior Investigators Meeting with Multiple Consortia
- NIH-HCA Meeting, March 2020
- Functional Proteomics Workshop, Aug 2020
- NIH Atlas Meeting, December 2020
- Cross-consortium Metadata WG
- Atlas to Practice Idea Lab September 2024
- NIH Spatial Biology Meeting (June 17–18, 2026)



Summary

Built for Scale and Collaboration

- NCI-funded network of Tumor Atlas and Pre-Cancer Atlas centers
- Multidisciplinary teams: clinical, experimental, computational
- Unified standards via a Data Coordinating Center

Addressing Areas Difficult for Individual Studies

- Multi-dimensional atlases from precancer through metastasis
- Tumor heterogeneity and microenvironment at single-cell resolution
- Biomarkers for detection, prognosis, and treatment response
- Generating new biological insights and hypotheses

Open Data the Community Can Use Today

- HTAN Data Portal: multi-omics, spatial, and imaging datasets
- FAIR-compliant, interoperable, integrated with NCI CRDC
- Tools for visualization, exploration, and download



**NATIONAL
CANCER
INSTITUTE**

www.cancer.gov

www.cancer.gov/espanol